(Q46727887)

24 December 2017

title

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta (English)

1 reference

24 December 2017

0 references

11

J Orav

1 reference

24 December 2017

Bianca Weinstock-Guttman

2

object named as

B Weinstock-Guttman

1 reference

24 December 2017

author name string

D R Smith

1

1 reference

24 December 2017

J A Cohen

3

1 reference

24 December 2017

X Wei

4

1 reference

24 December 2017

C Gutmann

5

1 reference

24 December 2017

R Bakshi

6

1 reference

24 December 2017

M Olek

7

1 reference

24 December 2017

L Stone

8

1 reference

24 December 2017

S Greenberg

9

1 reference

24 December 2017

D Stuart

10

1 reference

24 December 2017

W Stuart

12

1 reference

24 December 2017

H Weiner

13

1 reference

24 December 2017

publication date

1 October 2005

1 reference

24 December 2017

Multiple Sclerosis Journal

published in

1 reference

24 December 2017

volume

11

1 reference

24 December 2017

issue

5

1 reference

24 December 2017

page(s)

573-582

1 reference

24 December 2017

Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Immunogenicity of therapeutic proteins: clinical implications and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Quantitative follow-up of patients with multiple sclerosis using MRI: reproducibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Adaptive, template moderated, spatially varying statistical classification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1210OA

10.1191/1352458505MS1210OA

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

16193896

1 reference

24 December 2017